Vectus Biosystems Limited · ASX:VBS
Vectus Biosystems — Investor Presentation (May 2026)
21 slides from Vectus Biosystems's investor presentation, May 13, 2026
Slide 1: A differentiated approach to pulmonary fibrosis IPF
ASX: VBS al use only Phase 1A Safety Completed Phase 1B Next Value Inflection A differentiated approach to pulmonary fibrosis IPF Lead Indication Tara Speranza | CEO & CTO tsperanza@vectusbiosystems.com.au | vectusbiosystems.com.au
Slide 2: Forward-looking statements
Forward-looking statements: This Vectus Biosystems Limited (Vectus or the Company or ASX:VBS) presentation contains forward looking statements that involve risks and uncertainties. It has been prepared for informational purposes only. It does not constitute an offer or invitation to subscribe for, p
Slide 3: Capital Structure
CAPITAL STRUCTURE | ASX: VBS As at 12 May 2026 SHARE PRICE MARKET CAPITALISATION $0.125 $6.69M al use only per share (AUD) AUD CAPITAL STRUCTURE Shares on issue 53.54M Share price A$0.125 Market capitalisation A$6.69M Options ~A$7.06M 1.35M 3
Slide 4: The Problem: IPF Facts
THE PROBLEM IPF FACTS Idiopathic Pulmonary Fibrosis (IPF): A mostly fatal disease with no cure Incidence is rising; more common in men over 60 al use only Diagnosis often delayed 1–2 years after symptom Current therapies slow progression, none known to reverse fibrosis. onset Median survival: 2–5 ye
Slide 5: Orphan Drug Designation
ORPHAN DRUG DESIGNATION IPF is a rare disease. Vectus can target Orphan Drug Designation for VB0004 in IPF al use only 7-Year 10-Year Protocol User Fee Licensing US Exclusivity EU Exclusivity Assistance Waiver premium >US$4M Partners/ FDA EMA FDA/EMA FDA Acquirers IPF affects <200,000 Americans - me
Slide 6: Market Opportunity: A Platform Opportunity Across Fibrotic Disease
MARKET OPPORTUNITY A Platform Opportunity Across Fibrotic Disease Fibrosis underlies >40% of deaths globally. Vectus' lead program targets IPF first - with platform expansion potential across heart, kidney, and liver. al use only Addressable Market by Indication IPF: Lead Indication ~3M patients glo
Slide 7: Our Approach: VB0004 First-in-Class Antifibrotic with Human Safety Data
OUR APPROACH VB0004: First-in-Class Antifibrotic with Human Safety Data al use only z Differentiated Mechanism Favourable Drug Profile De-Risked Asset • Targets VIP pathway via NPR-C • Small molecule — oral, once-daily • Phase 1 SAD & MAD completed receptor dosing • Increases nitric oxide & cGMP • T
Slide 8: The Differentiation
THE DIFFERENTIATION The only known antifibrotic to reverse established disease in preclinical models VB0004 demonstrated reversal of established fibrosis in multiple preclinical organ models - a distinction no approved al use only therapy has achieved. VB0004 (Vectus) Nintedanib Pirfenidone Slows di
Slide 9: VB0004 Reverses Established Lung Fibrosis in Preclinical Model
PULMONARY FIBROSIS DATA VB0004 Reverses Established Lung Fibrosis in Preclinical Model 16-week Control al use only Pulmonary Fibrosis (% surface area) — Bleomycin Model Established pulmonary fibrosis — collagen deposition throughout lung parenchyma 25 -7% of 21 20 control 20 20-week Control (Vehicle
Slide 10: VB0004 Reverses Established Lung Fibrosis in Preclinical Model (Histology)
PULMONARY FIBROSIS DATA VB0004 Reverses Established Lung Fibrosis in Preclinical Model al use only 16-Week Fibrosis Model Control 20-Week Fibrosis Model Control VB0004 in Fibrosis Model at 20 Weeks Increased fibrosis (cyano), reduced capillaries Increasing fibrosis, decreasing capillaries Fibrosis r
Slide 11: Reversal of Established Fibrosis Across Multiple Organs
PRECLINICAL EVIDENCE Reversal of Established Fibrosis Across Multiple Organs Published peer-reviewed data from European Journal of Pharmacology. Dose-dependent effects; normal tissue architecture restored. al use only LUNG HEART KIDNEY VB0004 reversed established pulmonary fibrosis At highest dose (
Slide 12: Phase 1a Completed: Strong Safety & Predictable Pharmacokinetics
PHASE 1 RESULTS Phase 1a Completed: Strong Safety & Predictable Pharmacokinetics al use only SAD — Single Ascending Dose MAD — 14-Day Multiple Ascending Dose Max planned: 300mg Max planned: 100mg/day Max tolerated: 300mg Max tolerated: 100mg/day No significant adverse events No significant adverse e
Slide 13: Phase 1B: First Patient Data
Phase 1B: First Patient Data NEXT VALUE in Pulmonary Fibrosis INFLECTION This is the milestone that de-risks the program, establishes antifibrotic activity in humans, and positions VBS for Phase 2 and strategic partnership discussions. al use only Population: Mild pulmonary fibrosis / early ILD pati
Slide 14: Clinical Roadmap: Clear Path to Value Creation
CLINICAL ROADMAP Clear Path to Value Creation Phase 1a Phase 1B Phase 1B Phase 2 Completed Initiation KEY VALUE INFLECTION Read-out PoC al use only SAD + MAD IPF patients Recommended Efficacy signals No adverse events Biomarker data Phase 2 dose Partner-ready Pipeline Overview Program Lead Indicatio
Slide 15: Regulatory & Commercial Strategy
REGULATORY & COMMERCIAL STRATEGY Partnering-Led Model with Regulatory Acceleration Pathways COMMERCIALISATION MODEL al use only REGULATORY PATHWAY Out-licensing led Phase 1B → Phase 2 PoC Advance to Phase 1B/2 PoC, then regional or global licensing to Standard pathway; IPF patient population; biomar
Slide 16: Intellectual Property & Manufacturing
INTELLECTUAL PROPERTY & MANUFACTURING Broad IP Protection + Validated GMP Manufacturing GMP MANUFACTURING al use only PATENT PORTFOLIO • VB0004 composition-of-matter: granted USA, Europe, Japan, China, Two GMP centres validated Korea, Russia, Australia, Canada + others Process consistency confirmed
Slide 17: Leadership & Board
LEADERSHIP & BOARD Experienced Team Aligned to This Stage of Development Dr Tara Speranza Dr Ronald Shnier al use only CEO & CTO Non-Executive Chairman Radiologist; founder of one of Australia's first private MRI practices; 20+ years across scientific research, commercial strategy & capital former N
Slide 18: Milestone Strategy: De-Risking Milestones
MILESTONE STRATEGY De-Risking Milestones al use only Stage 1 Stage 2 Phase 1B initiation & execution Phase 2 PoC & partnering readiness • CRO engagement & Phase 1B trial costs • Phase 2 trial design & initiation • Biomarker panel & PK/PD analysis • GMP manufacturing scale-up • Regulatory preparation
Slide 19: Why Invest Now
WHY INVEST NOW Vectus Biosystems — The Investment Thesis al use only Unmet Need, Large Markets Differentiated & De-Risked Clear Next Catalyst IPF kills 2–5 years post-diagnosis. $5B+ 01 global market. No approved therapy 02 Phase 1 completed. Strong safety 03 Phase 1B in IPF patients is fully define
Slide 20: Get In Touch
GET IN TOUCH Dr Tara Speranza al use only ASX: VBS CEO & CTO Email: tsperanza@vectusbiosystems.com.au Web: vectusbiosystems.com.au ASX: VBS
Slide 21: VIP Target Validation - Appendix
VI P - T A RG E T VA L I D AT ION - A P P EN DIX Treatment with VIP reversed cardiac fibrosis in multiple animal Treatment with VIP was also found to reverse interstitial fibrosis in the models data from one was published in the paper entitled kidney in multiple animal models data from one was publi